Results 151 to 160 of about 4,008,604 (402)

Blood exosome connexins and small RNAs related to demyelinating disease activity

open access: yesAnnals of Clinical and Translational Neurology, Volume 12, Issue 3, Page 538-555, March 2025.
Abstract Objectives To assess blood exosome (Ex)‐connexin (Cx)43 (encoded by GJA1) and its truncated isoforms in multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), which show distinct alterations in astroglial Cx43. Methods Serum Exs from 48 patients with MS (34 relapsing–remitting, 14 secondary‐progressive), 35 with NMOSD, 20 ...
Guzailiayi Maimaitijiang   +12 more
wiley   +1 more source

Th17 Lymphocytes in Respiratory Syncytial Virus Infection

open access: yesViruses, 2013
Infection by respiratory syncytial virus (RSV) affects approximately 33 million infants annually worldwide and is a major cause of hospitalizations. Helper T lymphocytes (Th) play a central role in the immune response during such infections.
Rizgar A. Mageed   +4 more
doaj   +1 more source

The effect of swimming training and detraining on interleukin-17 and interleukin-18 of rats [PDF]

open access: yes, 2017
Background and aims: Interleukin-17 (IL-17) and interleukin-18 (IL-18) are proinflammatory cytokines. The aim of the present study was to investigate the effect of swimming trainings and detraining on IL-17 and IL-18 of rats.
araiesh, Ameneh.   +5 more
core  

Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression

open access: yesNature Communications, 2018
The gut microbiota has been causally linked to cancer, yet how intestinal microbes influence progression of extramucosal tumors is poorly understood. Here we provide evidence implying that Prevotella heparinolytica promotes the differentiation of Th17 ...
A. Calcinotto   +19 more
semanticscholar   +1 more source

Interleukin-17 in Drug Toxicity [PDF]

open access: yesClinical & Experimental Pharmacology, 2014
Drug-induced tissue injury is the most common cause for termination of preclinical and clinical trial processes of drug development. Many drugs approved for clinical use have been withdrawn from market or have been advised to use with caution because of unexpected adverse effects noticed during postmarketing survelliance.
openaire   +1 more source

Development of a Disease Model for Predicting Postoperative Delirium Using Combined Blood Biomarkers

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Postoperative delirium, a common neurocognitive complication after surgery and anesthesia, requires early detection for potential intervention. Herein, we constructed a multidimensional postoperative delirium risk‐prediction model incorporating multiple demographic parameters and blood biomarkers to enhance prediction accuracy ...
Hengjun Wan   +7 more
wiley   +1 more source

The Effect of Conventional Immunosuppressive Therapy on Cytokine Serum Levels in Pemphigus Vulgaris Patients

open access: yesIranian Journal of Allergy, Asthma and Immunology, 2014
Pemphigus vulgaris is an autoimmune disease, in which the role of Th17 cytokines needs to be further explored. This study was performed to assess serum levels of three interleukins (IL) required for Th17 differentiation (IL-1β, IL-6 and IL-23) and two ...
Hossein Mortazavi   +6 more
doaj  

Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling [PDF]

open access: yes, 2010
By binding to the interleukin 17 receptor (IL-17R), TRAF3 blocks formation of the IL-17R–Act1–TRAF6 complex and inhibits downstream ...
Gao, Hanchao   +10 more
core   +2 more sources

Interleukin-17: Potential Target for Chronic Wounds

open access: yesMediators of Inflammation, 2019
Chronic wounds exhibit persistent inflammation with markedly delayed healing. The significant burden of chronic wounds, which are often resistant to standard therapy, prompts further research on novel therapies.
Y. Hadian   +4 more
semanticscholar   +1 more source

Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy